Ophthalmology Times

top of page

This site was designed with the

website builder. Create your website today.Start Now

WELCOME

Search

ZEISS VISULAS Combi availability expands to Canada

ZEISS VISULAS Combi availability expands to Canada

Ophthalmology Times

Grace Koennecke

Mar 240 min read

0 views

0 comments

HanAll Biopharma receives Orphan Drug Designation in Japan for Batoclimab for thyroid eye disease

HanAll Biopharma receives Orphan Drug Designation in Japan for Batoclimab for thyroid eye disease

Ophthalmology Times

Grace Koennecke

Mar 180 min read

0 views

0 comments

Innovent Biologics announces approval of SYCUME in China for thyroid eye disease

Innovent Biologics announces approval of SYCUME in China for thyroid eye disease

Ophthalmology Times

Grace Koennecke

Mar 180 min read

0 views

0 comments

Data from Phase 2b of Opthea Limited wet AMD trial published

Data from Phase 2b of Opthea Limited wet AMD trial published

Ophthalmology Times

Grace Koennecke

Mar 60 min read

0 views

0 comments

Avirmax Biopharma prepares for IND-enabling study of ABI-201

Avirmax Biopharma prepares for IND-enabling study of ABI-201

Ophthalmology Times

Grace Koennecke

Mar 50 min read

0 views

0 comments

RetinalGenix Technologies begins testing remote ocular monitoring system

RetinalGenix Technologies begins testing remote ocular monitoring system

Ophthalmology Times

Grace Koennecke

Feb 270 min read

0 views

0 comments

The role of quantitative ultrawidefield angiography and machine learning

The role of quantitative ultrawidefield angiography and machine learning

Ophthalmology Times

Grace Koennecke

Feb 270 min read

0 views

0 comments

Perceive Pharma closes funding for $15M Series A therapy

Perceive Pharma closes funding for $15M Series A therapy

Ophthalmology Times

Grace Koennecke

Feb 260 min read

0 views

0 comments

Alcon to launch new SYSTANE PRO PF dry eye relief

Alcon to launch new SYSTANE PRO PF dry eye relief

Ophthalmology Times

Grace Koennecke

Feb 250 min read

0 views

0 comments

Axovia Therapeutics receives grant from A Race Against Blindness to support upcoming clinical trial

Axovia Therapeutics receives grant from A Race Against Blindness to support upcoming clinical trial

Ophthalmology Times

Grace Koennecke

Feb 120 min read

0 views

0 comments

Clearside Biomedical presents new data from CLS-AX ODYSSEY phase 2b trial

Clearside Biomedical presents new data from CLS-AX ODYSSEY phase 2b trial

Ophthalmology Times

Grace Koennecke

Feb 110 min read

0 views

0 comments

MERIT acquires OSOD to enhance ophthalmic drug development

MERIT acquires OSOD to enhance ophthalmic drug development

Ophthalmology Times

Grace Koennecke

Feb 40 min read

0 views

0 comments

Prevent Blindness names February as AMD and Low Vision Awareness Month

Prevent Blindness names February as AMD and Low Vision Awareness Month

Ophthalmology Times

Grace Koennecke

Feb 40 min read

0 views

0 comments

Harrow launches Harrow Cares program in partnership with Cencora

Harrow launches Harrow Cares program in partnership with Cencora

Ophthalmology Times

Grace Koennecke

Jan 290 min read

0 views

0 comments

Viralgen and Axovia Therapeutics partner to manufacture gene therapy for Bardet-Biedl Syndrome

Viralgen and Axovia Therapeutics partner to manufacture gene therapy for Bardet-Biedl Syndrome

Ophthalmology Times

Grace Koennecke

Jan 280 min read

0 views

0 comments

ARVO Foundation reveals 2025 Dr David L Epstein Award recipients

ARVO Foundation reveals 2025 Dr David L Epstein Award recipients

Ophthalmology Times

Grace Koennecke

Jan 280 min read

0 views

0 comments

Norlase receives FDA 510(k) clearance and CE mark for LYNX pattern scanning laser indirect ophthalmoscope

Norlase receives FDA 510(k) clearance and CE mark for LYNX pattern scanning laser indirect ophthalmoscope

Ophthalmology Times

Grace Koennecke

Jan 270 min read

0 views

0 comments

Ashvattha Therapeutics secures $50M in financing to advance clinical trials

Ashvattha Therapeutics secures $50M in financing to advance clinical trials

Ophthalmology Times

Grace Koennecke

Jan 150 min read

0 views

0 comments

RhyGaze secures Series A financing of $86 million to further novel gene therapy

RhyGaze secures Series A financing of $86 million to further novel gene therapy

Ophthalmology Times

Grace Koennecke

Jan 150 min read

0 views

0 comments

The implications of real-world data integration in health care and ophthalmology

The implications of real-world data integration in health care and ophthalmology

Ophthalmology Times

Grace Koennecke

Sep 9, 20240 min read

0 views

0 comments

bottom of page